Skip to main content
ARDELYX, INC. logo

ARDELYX, INC. — Investor Relations & Filings

Ticker · ARDX ISIN · US0396971071 LEI · 549300F542QR4SXHCY32 US Manufacturing
Open in API
Filings indexed 1,078 across all filing types
Latest filing 2017-04-25 Proxy Solicitation & In…
Country US United States of America
Listing US ARDX

About ARDELYX, INC.

https://www.ardelyx.com/

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines to address unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Its key commercial product is XPHOZAH® (tenapanor), a novel mechanism therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Ardelyx also develops treatments for Irritable Bowel Syndrome with Constipation (IBS-C), aiming to advance patient care through its portfolio of innovative therapies.

Recent filings

Filing Released Lang Actions
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2017-04-25 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC under the Securities Act of 1933. It is a registration statement for securities offerings, describing the types of securities to be offered (common stock, preferred stock, debt securities, warrants, purchase contracts, units) and the maximum aggregate offering price. It includes details about the registration fee, the offering process, and legal disclaimers. This type of filing is related to capital raising and financing activities, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update filings.
2017-04-24 English
FORM 4
Director's Dealing
2017-04-22 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content focuses on updates about clinical trial progress and projections, which are operational updates rather than financial results or detailed reports. The document is relatively short (2623 characters) and does not contain financial statements or detailed analysis. It is not an earnings release, annual report, or interim report. It is also not a certification or voting result. The nature of the update fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous filings that do not fit other specific categories. Therefore, the correct classification is Regulatory Filings (RNS).
2017-03-21 English
FORM 4
Director's Dealing
2017-03-15 English
FORM 8-K
Regulatory Filings
2017-03-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.